Biomarker discovery and development in pediatric critical care medicine

被引:74
作者
Kaplan, Jennifer M.
Wong, Hector R. [1 ]
机构
[1] Univ Cincinnati, Coll Med, Div Crit Care Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA
基金
美国国家卫生研究院;
关键词
biomarker discovery and development; pediatric intensive care unit; multibiomarker-based risk model; pediatric septic shock; procalcitonin; interleukin-8; acute kidney injury; C-REACTIVE PROTEIN; GELATINASE-ASSOCIATED LIPOCALIN; ACUTE KIDNEY INJURY; CALCITONIN-I GENE; INFLAMMATORY RESPONSE; BACTERIAL-INFECTION; ILL CHILDREN; SYSTEMIC INFLAMMATION; SERUM PROCALCITONIN; SEPSIS;
D O I
10.1097/PCC.0b013e3181e28876
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objectives: To frame the general process of biomarker discovery and development; and to describe a proposal for the development of a multibiomarker-based risk model for pediatric septic shock. Data Source: Narrative literature review and author-generated data. Data Selection: Biomarkers can be grouped into four broad classes, based on the intended function: diagnostic, monitoring, surrogate, and stratification. Data Extraction and Synthesis: Biomarker discovery and development requires a rigorous process, which is frequently not well followed in the critical care medicine literature. Very few biomarkers have successfully transitioned from the candidate stage to the true biomarker stage. There is great interest in developing diagnostic and stratification biomarkers for sepsis. Procalcitonin is currently the most promising diagnostic biomarker for sepsis. Recent evidence suggested that interleukin-8 can be used to stratify children with septic shock having a high likelihood of survival with standard care. Currently, there is a multi-institutional effort to develop a multibiomarker-based sepsis risk model intended to predict outcome and illness severity for individual children with septic shock. Conclusions: Biomarker discovery and development are an important portion of the pediatric critical care medicine translational research agenda. This effort will require collaboration across multiple institutions and investigators. Rigorous conduct of biomarker-focused research holds the promise of transforming our ability to care for individual patients and our ability to conduct clinical trials in a more effective manner. (Pediatr Crit Care Med 2011; 12:165-173)
引用
收藏
页码:165 / 173
页数:9
相关论文
共 61 条
  • [41] Protein biomarker discovery and validation: the long and uncertain path to clinical utility
    Rifai, Nader
    Gillette, Michael A.
    Carr, Steven A.
    [J]. NATURE BIOTECHNOLOGY, 2006, 24 (08) : 971 - 983
  • [42] Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade
    Rooney, Terence
    Roux-Lombard, Pascale
    Veale, Douglas J.
    FitzGerald, Oliver
    Dayer, Jean-Michel
    Bresnihan, Barry
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (04) : 706 - 714
  • [43] Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections The ProHOSP Randomized Controlled Trial
    Schuetz, Philipp
    Christ-Crain, Mirjam
    Thomann, Robert
    Falconnier, Claudine
    Wolbers, Marcel
    Widmer, Isabelle
    Neidert, Stefanie
    Fricker, Thomas
    Blum, Claudine
    Schild, Ursula
    Regez, Katharina
    Schoenenberger, Ronald
    Henzen, Christoph
    Bregenzer, Thomas
    Hoess, Claus
    Krause, Martin
    Bucher, Heiner C.
    Zimmerli, Werner
    Mueller, Beat
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (10): : 1059 - 1066
  • [44] Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis
    Simon, L
    Gauvin, F
    Amre, DK
    Saint-Louis, P
    Lacroix, J
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) : 206 - 217
  • [45] Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome
    Simon, Liliana
    Saint-Louis, Patrick
    Amre, Devendra K.
    Lacroix, Jacques
    Gauvin, France
    [J]. PEDIATRIC CRITICAL CARE MEDICINE, 2008, 9 (04) : 407 - 413
  • [46] Snider RH, 1997, J INVEST MED, V45, P552
  • [47] National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
    Sturgeon, Catharine M.
    Duffy, Michael J.
    Stenman, Ulf-Hakan
    Lilja, Hans
    Brunner, Nils
    Chan, Daniel W.
    Babaian, Richard
    Bast, Robert C., Jr.
    Dowell, Barry
    Esteva, Francisco J.
    Haglund, Caj
    Harbeck, Nadia
    Hayes, Daniel F.
    Holten-Andersen, Mads
    Klee, George G.
    Lamerz, Rolf
    Looijenga, Leendert H.
    Molina, Rafael
    Nielsen, Hans Jorgen
    Rittenhouse, Harry
    Semjonow, Axel
    Shih, Ie-Ming
    Sibley, Paul
    Soletormos, Gyorgy
    Stephan, Carsten
    Sokoll, Lori
    Hoffman, Barry R.
    Diamandis, Eleftherios P.
    [J]. CLINICAL CHEMISTRY, 2008, 54 (12) : E11 - E79
  • [48] Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis
    Tang, Benjamin M. P.
    Eslick, Guy D.
    Craig, Jonathan C.
    McLean, Anthony S.
    [J]. LANCET INFECTIOUS DISEASES, 2007, 7 (03) : 210 - 217
  • [49] Interleukin-18: A novel prognostic cytokine in bacteria-induced sepsis
    Tschoeke, SK
    Oberholzer, A
    Moldawer, LL
    [J]. CRITICAL CARE MEDICINE, 2006, 34 (04) : 1225 - 1233
  • [50] Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis
    Uzzan, Bernard
    Cohen, Regis
    Nicolas, Patrick
    Cucherat, Michel
    Perret, Gerard-Yves
    [J]. CRITICAL CARE MEDICINE, 2006, 34 (07) : 1996 - 2003